| 查看: 503 | 回复: 1 | ||
[资源]
职业发展 白皮书- The continuing evolution of the Pharmaceutical Industry
|
|
RegentAtlantic Capital, LLC is pleased to present our white paper entitled “The Continuing Evolution of the Pharmaceutical Industry: Career Challenges and Opportunities”. http://www.pharmawealthmanager.c ... Y%20Nov-30-2007.pdf The Continuing Evolution of the Pharmaceutical Industry: Career Challenges and Opportunities December 2007 Michael Steiner, CFP®, CPA David H. Bugen, CFP®, MBA Brian Kazanchy, CFP®, CFA, MBA William T. Knox IV, CFP®, CFA, JD Margaret V. Prentice, MBA Lauren Goldfarb Mark P. Hurley Steven E. Cortez Christine L. Boudreaux Benjamin J. Robins Yvonne N. Kanner Shehzad Sippy Adam L. Bartkoski Ana M. Avila are Changing the Industry and the Careers of its Participants ............................................................. 3 Revenues are Under Pressure ................................................. 3 Costs and Risks of Developing New Drugs are Increasing ....... 3 Globalization ............................................................................ 4 Big Changes for the Pharmaceutical Industry .................................. 4 Corporate Restructuring .......................................................... 5 Adoption of Risk Reduction Strategies ..................................... 5 Evolution of Drug Marketing ..................................................... 6 What Does it all Mean to an Industry Professional? .......................... 6 Six Future High Growth Areas of the Industry .................................. 6 Commercialization of Dormant Compounds ............................ 7 Generic or Biosimilar Versions of Biologics .............................. 7 Improving the Effi ciency of R&D ............................................... 7 Oncology and Central Nervous System (CNS) Disorders Research ......................................................... 7 Stratifi ed Medicine and Diagnostics ......................................... 7 Fusion of Pharmaceuticals and Consumer Goods ................... 8 Seven Highly-Valued Skill Sets ......................................................... 8 Ability to Manage Decentralized Intellectual Capital Resources .....8 Ability to Work in Joint Ventures and Across Divisions, Cultures and Countries.................................................... 8 Ability to Integrate an Understanding of Intellectual Property Laws, Scientifi c Expertise and Business Strategy ..................................................... 9 Ability to Spur Creativity While Managing Commercially ........... 9 Knowledge and Insight on the Decision-Making Dynamics of Payers ........................................................ 9 Expertise in the Functioning and Decision-Making of Regulatory Agencies ................................................. 10 Human Resource Skills to Help Transform Pharmaceutical Companies ................................................................... 10 Every Industry Participant will Experience Change ......................... 10 Conclusion .................................................................................... 11 II. An Industry Forced to Change ................................ 12 Forces Shaping the Pharmaceutical Industry ................................. 12 Industry Revenues are Under Pressure .................................. 12 Costs and Risks are Increasing .............................................. 23 Globalization .......................................................................... 27 Big Changes for the Pharmaceutical Industry ................................ 30 Limited and Unattractive Choices .......................................... 30 Changes Have Already Begun ............................................... 31 Dislocation of a Generation of Upper-Middle and Senior-Level Executives ................................................. 32 Mergers and Acquisitions as a Cost-Cutting Strategy ............ 33 Refocused Strategies with Fewer Treatment Lines ................. 35 Acquiring Instead of Developing Compounds ........................ 36 Research Consortiums Share Risk ......................................... 37 Outsourcing of R&D to Foreign Laboratories .......................... 38 Evolution of Marketing ........................................................... 38 A Very Different Industry ................................................................ 40 III. Opportunities for the Next Decade ......................... 42 A New Golden Era ......................................................................... 42 Six High-Growth Areas .................................................................. 43 Commercialization of Dormant Compounds .......................... 43 Generic or Biosimilar Versions of Biologics ............................ 44 Improving the Effi ciency of R&D ............................................. 47 Oncology and Central Nervous System (CNS) Disorders Research ....................................................... 48 Stratifi ed Medicine and Diagnostics ....................................... 50 Fusion of Pharmaceuticals and Consumer Goods ................. 51 Seven Skill Sets with Great Future Value ........................................ 52 Ability to Manage Decentralized Intellectual Capital Resources .......................................................... 52 Ability to Work in Joint Ventures and Across Divisions, Cultures and Countries.................................................. 53 Ability to Integrate an Understanding of Intellectual Property Laws, Scientifi c Expertise and Business Strategy ................................................... 54 Ability to Spur Creativity While Managing Commercially ......... 55 Knowledge and Insight on the Decision-Making Dynamics of Payers ....................................................................... 57 Expertise in the Functioning and Decision-Making of Regulatory Agencies ..................................................... 58 Human Resource Skills to Help Transform Pharmaceutical Companies ................................................................... 59 IV. Planning Your Future ................................................ 60 Step 1: Taking Responsibility for Your Career Planning .................. 60 Step 2: Assessing the Industry’s Future Structure and Your Tolerance for Risk ........................................................ 61 The Shifting Structure of the Pharmaceutical Industry ............ 61 Cultures Vary by Size of Enterprise ........................................ 62 The Risk vs. Reward Calculus ................................................ 65 Step 3: Evaluating Your Financial Resources and the Economic Impact of a Career Change ........................................ 67 Evaluating Your Asset Allocation and the Concentration Risk Borne by Many in the Pharmaceutical Industry .............. 69 Leaving an Employer Will Often Involve Hidden Costs ............ 72 Understanding Risks Involved in Taking a New Job ................ 77 Step 4: Figuring Out Who You Are and How to Brand Yourself ...... 82 Athletes vs. Specialists .......................................................... 82 Developing a Personal Branding Strategy .............................. 84 A Final Thought: Begin with a Comprehensive Self-Assessment .... 86 V. Conclusion ................................................................ 87 VI. Appendix.................................................................... 88 |
» 猜你喜欢
070700求调剂
已经有1人回复
求调剂总分327
已经有1人回复
药理学论文润色/翻译怎么收费?
已经有105人回复
BL21(DE3)UV或者丝裂霉素诱导条件下会释放DE3的噬菌体吗?
已经有479人回复
使用MolAICal生成小分子CHARMM力场拓扑和参数文件
已经有0人回复
扩散模型生成分子目前痛点,改进方向有哪些,论文创新性卡住了现在
已经有0人回复
求解答药物生成模型痛点以及创新点,扩散模型创新
已经有0人回复
多糖提取纯化结构表征和活性
已经有0人回复
英国贝尔法斯特女王大学药物递送方向招CSC博士生
已经有1人回复
Materials Today Chemistry和AMH哪个投稿快啊
已经有0人回复
2楼2013-12-20 12:24:28










回复此楼